A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806
NCT01801293
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
RSV Infection
Interventions
DRUG:
GS-5806
Sponsor
Gilead Sciences